Full Title: A Phase II, Open Label, Randomised Study of Ipilimumab with Temozolomide versus Temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma
Sponsor: University of Oxford
This is an unblinded, open labelled stratified randomised Phase II multicentre clinical trial (CTIMP). Patients with newly diagnosed de-novo glioblastoma following surgery or biopsy and radical radiotherapy with concomitant temozolomide will be recruited from 5-7 sites in the UK.
To evaluate whether the addition of ipilimumab to the current standard of care following surgery and chemoradiotherapy will improve survival in patients with newly diagnosed glioblastoma
To evaluate the safety and tolerability of ipilimumab plus temozolomide
Target Opening to Recruitment: 1st October 2018
Funding: The study is funded by Bristol Myers-Squibb, The National Brain Appeal and UCLH Charities